DM
GBT

Deerfield Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Deerfield Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-251,000
Closed -$20M – 104
2019
Q4 		$20M Sell
251,000
-17,100
-6% -$1.01M 0.64% 49
2019
Q3 		$13M Buy
268,100
+33,100
+14% +$1.72M 0.53% 56
2019
Q2 		$12.4M Buy
+235,000
New +$13.5M 0.44% 65
2017
Q1 		– Sell
-171,428
Closed -$2.48M – 114
2016
Q4 		$2.48M Hold
171,428
– – 0.1% 88
2016
Q3 		$3.95M Sell
171,428
-1,562,400
-90% -$29.8M 0.18% 66
2016
Q2 		$28.8M Buy
1,733,828
+540,017
+45% +$10.9M 1.13% 34
2016
Q1 		$18.9M Buy
1,193,811
+30,000
+3% +$533K 0.81% 44
2015
Q4 		$37.6M Buy
1,163,811
+273,191
+31% +$11.8M 1.52% 15
2015
Q3 		$37.5M Buy
+890,620
New +$42M 1.45% 20

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Deerfield Management's GBT Position: Q1 2020 in Review

Deerfield Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2020, closing a stake of 251,000 shares — an estimated $20M sold.

Deerfield Management first reported a position in GBT in Q3 2015 and held it in 9 quarters. The position peaked at $37.6M in Q4 2015. 220 funds tracked by Wall St. Rank hold GBT as of Q1 2020.

  • Deerfield Management reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Deerfield Management sold 251,000 Global Blood Therapeutics, Inc. shares in Q1 2020, an estimated $20M.
  • Deerfield Management first reported a position in Global Blood Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
  • Deerfield Management's Global Blood Therapeutics, Inc. position peaked at $37.6M in Q4 2015.
  • 220 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2020.

Based on Deerfield Management's 13F filing for Q1 2020, filed 15 May 2020.